Dr. Fava to advise on the clinical development of KETABET for Major Depressive Disorder TORONTO, March 16, 2021 (GLOBE NEWSWIRE) — Newscope Capital Corporation (the “Company” or “Newscope”) (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals…


Previous articlePerception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders
Next articleOptimi Health Receives Health Canada NPN Product Licenses in Preparation for Q2 Sales Launch